Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,221
datasets available to search
ShareScore release 0.9.0
Dataset results
6,221 results for “Cancer therapy”
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acr
ClinicalTrials.gov study NCT03447769. IPD Sharing: YES. Countries: 41. Publications: 1.
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
ClinicalTrials.gov study NCT02034110. IPD Sharing: YES. Countries: 14. Publications: 8.
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progres
ClinicalTrials.gov study NCT03056755. IPD Sharing: YES. Countries: 19. Publications: 4.
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
ClinicalTrials.gov study NCT03284957. IPD Sharing: YES. Countries: 10. Publications: 1.
Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy
Open the record for dataset details and reuse information.
Replication Data for: Precision Oncology, Cell Signaling and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutics
<p>In recent decades, there has been a deluge in the large-scale production of anticancer agents, primarily due to advances in genomic technologies enabling precise targeting of oncogenic pathways involved in disease progression. This initiated a paradigm shift in cancer research and therapeutics based on the ability to study molecular changes throughout the genome. It provided a unique opportunity in the field of translational cancer research and have led to the concept of precision medicine in cancer therapy, raising hopes of developing better diagnostic and therapeutic means for the management of cancer. The purpose of this article is to briefly review the tools and techniques involved in precision oncology research and their applications in the field of cancer treatment. </p>
Data sets used to demonstrate the software MadHitter in the manuscript "The Landscape of Receptor-Mediated Precision Cancer Combination Therapy Via a Single-Cell Perspective"
<p>This is a zip archive of nine single-cell RNASeq data sets used in the manuscript entitled:</p> <p>"The Landscape of Receptor-Mediated Precision Cancer Combination Therapy Via A Single-Cell Perspective" by Saba Ahmadi, Pattara Sukprasert, Rahulsimham Vegesna, Sanju Sinha, Fiorella Schischlik, Natalie Artzi, Samir Khuller, Alejandro A. Schaffer, Eytan Ruppin,</p> <p>The README.txt describes the data sets in detail.</p> <p>The associated software can be found at https://github.com/ruppinlab/madhitter</p>
Common anti-cancer therapies induce somatic mutations in stem cells of healthy tissue
<p>Genome-wide mutation analyses have revealed that specific anti-cancer drugs are highly mutagenic to cancer cells, but the mutational impact of anti-cancer therapies on normal cells is not known. Here, we examine genome-wide somatic mutation patterns in 42 healthy adult stem cells (ASCs) of the colon or the liver from 14 colorectal cancer patients (mean of 3.2 ASC per donor) that received systemic chemotherapy and/or radiotherapy. The platinum-based chemo-drug Oxaliplatin induces on average 535±260 mutations in colon ASC, while 5-FU shows a complete mutagenic absence in most colon ASCs. In contrast with the colon, normal liver ASCs escape mutagenesis from systemic treatment. Radiation results in the accumulation of 50-100 5-10,000bp deletions and structural rearrangements in colon ASCs. Thus, while chemotherapies are highly effective at killing cancer cells, their systemic use also increases the mutational burden of long-lived normal stem cells responsible for tissue renewal thereby increasing the risk for developing second cancers.</p>
Overcoming nutritional immunity by engineering iron-scavenging bacteria for cancer therapy
<p>Certain bacteria demonstrate the ability to target and colonize the tumor microenvironment, a characteristic that positions them as innovative carriers for delivering various therapeutic agents in cancer therapy. Nevertheless, our understanding of how bacteria adapt their physiological condition to the tumor microenvironment remains elusive. In this work, we employed liquid chromatography-tandem mass spectrometry to examine the proteome of <em>E. coli</em> colonized in murine tumors. Compared to <em>E. coli </em>cultivated in the rich medium, we found that <em>E. coli </em>colonized in tumors notably upregulated the processes related to ferric ions, including enterobactin biosynthesis and iron homeostasis. This finding indicated that the tumor is an iron-deficient environment to <em>E. coli</em>. We also found that the colonization of <em>E. coli </em>in the tumor led to an increased expression of lipocalin 2 (LCN2), a host protein that can sequester enterobactin. We therefore engineered <em>E. coli</em> to evade the nutritional immunity provided by LCN2. By introducing the IroA cluster, the <em>E. coli</em> synthesizes the glycosylated enterobactin, which creates steric hindrance to avoid the LCN2 sequestration. The IroA-<em>E. coli</em> showed enhanced resistance to LCN2 and significantly improved the anti-tumor activity in mice. Moreover, the mice were cured by the IroA-<em>E. coli </em>treatment became resistant to the tumor re-challenge, indicating the establishment of immunological memory. Overall, our study underscores the crucial role of bacteria's ability to acquire ferric ions within the tumor microenvironment for effective cancer therapy.</p>
Peripheral blood TCRseq data in AIRR-C format for cancer patients who received either photon or proton based radiation therapy
<p>These are the AIRR-C format converted data from the original Adaptive ImmunoSEQ v2 data format.</p> <p>See the analysis repo for more information: <a href="https://github.com/JamieHeather/radiation-induced-lymphopenia-paper-analysis" target="_blank" rel="noopener">https://github.com/JamieHeather/radiation-induced-lymphopenia-paper-analysis</a>.</p>
Matrix stiffness influences response to chemo and targeted therapy in brain metastatic breast cancer cells
Open the record for dataset details and reuse information.
Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalised therapy
<div> <div> <div> <p>Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, a disease with dismal overall survival. Advances in treatment are hindered by a lack of preclinical models. Here we show how a personalised organotypic 'avatar' created from resected tissue, allows spatial and temporal reporting on a complete in situ tumour microenvironment, and mirrors clinical responses. Our perfusion culture method extends tumour slice viability, maintaining stable tumour content, metabolism, stromal composition, and immune cell populations for 12 days. Using multiplexed immunofluorescence and spatial transcriptomics, we identify immune neighbourhoods and potential for immunotherapy. We employed avatars to assess the impact of a pre-clinically validated metabolic therapy and show recovery of stromal and immune phenotypes and tumour re-differentiation. To determine clinical relevance, we monitored avatar response to gemcitabine treatment and identified a patient avatar-predicable response from clinical follow-up. Thus, avatars provide valuable information for the syngeneic testing of novel therapeutics and a truly personalised therapeutic assessment platform for patients.</p> </div> </div> </div>
HINC dataset from: Homeopathic treatment as an add-on therapy may improve quality of life and prolong survival in patients with non-small cell lung cancer: A prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study
<p class="CxSpFirst"><b>Background:</b> Patients with advanced non-small cell lung cancer (NSCLC) have limited treatment options. Alongside conventional anticancer treatment, additive homeopathy might help to alleviate side effects of conventional therapy. The aim of the present study was to investigate whether additive homeopathy might influence quality of life (QoL) and survival in NSCLC patients.</p> <p class="CxSpMiddle"><b>Methods:</b> In this prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter, phase III study, we evaluated the possible effects of additive homeopathic treatment compared with placebo in NSCLC stage IV patients with respect to QoL in the two randomized groups and survival time in all three groups. Treated patients visited the outpatients' centers every 9 weeks. 150 Patients with stage IV NSCLC were included in the study. 98 received either individualized homeopathic remedies (n=51) or placebo (n=47) in a double-blinded fashion. 52 control patients without any homeopathic treatment were observed for survival only. The constituents of the different homeopathic remedies were mainly of plant, mineral or animal origin. The remedies were manufactured by stepwise dilution and succussion, thereby preparing stable Good Manufacturing Practice grade formulations.</p> <p class="CxSpMiddle"><b>Results:</b> QoL as well as functional and symptom scales showed significant improvement in the homeopathy group when compared with placebo after 9 and 18 weeks of homeopathic treatment (p<0.001). Median survival time was significantly longer in the homeopathy group (435 days) vs placebo (257 days; p=0.010) as well as vs control (228 days; p<0.001). Survival rate in the homeopathy group differed significantly from placebo (p=0.020) and from control (p<0.001).</p> <p class="CxSpMiddle"><b>Conclusion:</b> QoL improved significantly in the homeopathy group compared with placebo. In addition, survival was significantly longer in the homeopathy group versus placebo and control. A higher QoL might have contributed to the prolonged survival. The study suggests that homeopathy positively influences not only QoL but also survival. Further studies including other tumor entities are warranted.</p>
The Magee 3 Equation Predicts Favorable Pathologic Response to Neoadjuvant Endocrine Therapy in Breast Cancer Patients
<p><strong>Supplementary Figure 1: </strong>Comparison between ROC curves of ME1, ME2, ME3, and MEm scores in a sample of breast cancer patients undergoing neoadjuvant endocrine therapy.</p> <p><strong>Supplementary Figure 2: </strong>ROC curves with their respective confidence intervals and AUC values in the sample of breast cancer patients, excluding those with clinical stage IA tumors. A: ME1. B: ME2. C: ME3. D: MEm.</p> <p><strong>Supplementary Figure 3:</strong> Comparison between ROC curves of ME1, ME2, ME3, and MEm scores in the sample of breast cancer patients undergoing neoadjuvant endocrine therapy (excluding those with clinical stage IA tumors).</p> <p> </p>
High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients
<p>High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients</p>
Supplemental Data for "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"
<p>Supplemental data files for Bahnassy et al, "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"</p>
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
ClinicalTrials.gov study NCT04406857. IPD Sharing: YES. Countries: 1. Publications: 1.
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
ClinicalTrials.gov study NCT01242800. IPD Sharing: YES. Countries: 5. Publications: 1.
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
ClinicalTrials.gov study NCT00003377. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Proton Therapy in Adjuvant Pancreatic Cancer
ClinicalTrials.gov study NCT03885284. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.